REDWOOD CITY, Calif. -- (BUSINESS WIRE) -- Vantage Health, Inc. (OTCQB: VNTH) ("Vantage Health" or the "Company"), announced today an article which was published by Adrienne LaFrance of The Atlantic, an on-line publication and magazine, entitled “A Breathalyzer That Can Diagnose Cancer”.
For the past two decades, Raed Dweik, a doctor who runs the pulmonary vascular program at the Cleveland Clinic’s Respiratory Institute has been studying the molecular patterns in the breath that can reveal what’s happening inside the body.
Dr. Dweik cites in the article, “The Holy Grail of breath testing would be a breathalyzer-style device that a person could carry in her pocketbook and use anytime.”
Vantage Health, Inc. is developing such a device, the Vantage Health Sensor, with clinical trials planned for later this year. To view the articles please click on the following links:
About Vantage Health Inc.
Vantage Health Inc. - a leading mobile health technology company - is developing personalized and point-of-care screening using Apps based upon chemical sensing residing within a small device attached to a smartphone.
With its foundations in advanced nanotechnology, the company’s first product, the Vantage Health Sensor, is the convergence of nano-electronics, bio-informatics, and wireless technology to create the next generation mobile health application. The first mobile App is expected to be for lung cancer screening with additional mobile healthcare Apps in the planning stages. The company has offices in Redwood City, CA and New York. For more information, please visit http://www.vantagehealthinc.com
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things statements with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions. Such forward-looking statements may also include statements, among other things, concerning the efficacy, safety and intended utilization of Vantage’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include, among others, the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Vantage may not obtain approval to market its product candidates, or outside financing may not be available to meet capital requirements. These forward-looking statements are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including economic conditions, technological change, regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary significantly from what we currently foresee.
For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s most recent Annual Report on Form 10-K and other periodic and other filings Vantage files with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Vantage assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.